Allbirds is a very modern corporate tragedy.

A decent product gets early love.
The market decides it is not just a shoe company but a movement.
Bankers arrive.
A narrative gets marked up faster than the business.
Then reality turns up and asks the sort of rude questions that PowerPoint tends to avoid.

At its peak, Allbirds was worth about $4.1bn after its 2021 listing. Last week it agreed to sell its assets for $39m. That is not a stumble. That is a live demonstration of what happens when valuation gets drunk on story.

The mistake was not sustainability.
The mistake was thinking sustainability was enough.

Customers do not buy shoes because your carbon disclosure is beautifully typeset.
They buy because the product looks good, feels good, lasts, and says something about them.

Allbirds started with a sharp product and then wandered into the usual brand executive fantasy camp of line extension, store expansion, and category sprawl. Meanwhile revenue kept sliding, losses stayed ugly, and management ended up shutting remaining full price US stores to chase a more capital light model. (Allbirds, Inc.)

This is the bit a lot of operators, boards, and investors still refuse to admit.

Brand is not a substitute for economics.
Mission is not a moat.
DTC is not a business model. It is a route to market.
And a lovely story told to the wrong customer at the wrong price is still just expensive theatre.

Private equity should pay attention here too.
There is a reason I keep banging on about value creation being operational, not cosmetic.
Too many businesses are still being sold as if a better deck, a shinier purpose statement, and a few growth buzzwords can suspend gravity.
They cannot.
Not in shoes.
Not in software.
Not in portfolio companies.

The harsh lesson from Allbirds is brutally simple.

If the product is not strong enough, the brand story becomes a tax.
If the economics are not strong enough, growth becomes self harm.
And if the valuation runs miles ahead of the underlying business, the ending is usually less Nike and more autopsy.